A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

To join this study, you would need to have been diagnosed with multiple myeloma and it needs to be measurable, meaning doctors can track its progress through blood or urine tests. You should have already received between one and three different anti-cancer treatments for your myeloma, and these must have included a specific type of antibody treatment (anti-CD38 monoclonal antibody) and another medication called lenalidomide, each for at least two cycles. Importantly, your myeloma must have either progressed, meaning it's getting worse, or not responded well to your last treatment.

There are also some health checks you'd need to meet. Your general health and ability to perform daily activities would be assessed using a standard scale (ECOG performance status score of 0 to 2), indicating you're well enough to participate. If you are female, you must not be pregnant, breastfeeding, or planning to become pregnant during the study and for six months afterwards. You must also be able to follow the study's requirements and attend appointments.

However, some things would mean you couldn't join. For example, if you've already received any treatment specifically targeting something called BCMA, you wouldn't be eligible. Also, if you've previously taken pomalidomide, or have certain nerve issues (peripheral neuropathy), or specific allergies to the drugs used in the comparison treatment (PVd), you might not be able to participate. The study team will review all your medical information carefully to see if it's the right fit for you.

If you decide to take part in this study, you will either receive the new treatment, teclistamab, or one of the existing standard treatments (PVd or Kd). The treatment will be given according to a set schedule. You will have regular visits to the hospital for assessments such as blood tests, urine tests, and other health checks to monitor your progress and check for any side effects. These visits are important for the research team to understand how the treatment is working for you. You will also have ongoing contact with the study team to discuss your health and any concerns you might have. The total duration of your participation, including follow-up after the main treatment period, will depend on your individual response and the study protocol, but the team will explain this clearly before you start.